Аннотация:
One of modern approaches in the development of new-generation drugs is the design of original dosage forms based on substances of a known spectrum of action using modern innovative technologies that make it possible to obtain drugs with high therapeutic efficiency and with minimal side effects. The invention relates to the pharmaceutical industry and is an innovative pharmaceutical substance, which can be used both independently and in combination with enzymes of the hydrolase class, that are capable of breaking down peptides and proteins, and anesthetic agents for the treatment of infected wounds of various genesis. The chitosan-miramistin complex has multiresistance to antibiotics, enhances functional activity of immune cells by stimulating local nonspecific immunity, promotes antigen capturing by macrophages and its accumulation in the lysosomal fraction, and does not have a local irritant effect. © 2018, Pharmainfo Publications. All rights reserved.
Ключевые слова:
Chitosan-miramistin complex (CMC); Chlorhexidine; Lysozyme; Miramistin; Treatment of infected wounds of various genesis
antiinfective agent; chitosan; chlorhexidine; lysozyme; miramistin; n acetylglucosamine; polysaccharide; unclassified drug; agar diffusion; antibacterial activity; Article; biocompatibility; cell proliferation; controlled study; drug formulation; drug potentiation; drug stability; Escherichia coli; fibroblast; freeze drying; immobilization; immune response; immunity; nonhuman; Staphylococcus aureus; wound infection
Brkich L. L. Liliana Lyubanovna 1990-
Pyatigorskaya N. V. Natal`ya Valeryevna 1965-
Brkich G. E`. Galina E`duardovna 1967-
Belov A. A.
Krasnyuk I. I. Ivan Ivanovich 1955-
Бркич Л. Л. Лилиана Любановна 1990-
Пятигорская Н. В. Наталья Валерьевна 1965-
Бркич Г. Э. Галина Эдуардовна 1967-
Белов А. А.
Краснюк И. И. Иван Иванович 1955-
Miramistin as an antimicrobial component in the innovative substance of Chitosan-Miramistin Complex (CMC) for the treatment of infected wounds of various genesis
Miramistin as an antimicrobial component in the innovative substance of Chitosan-Miramistin Complex (CMC) for the treatment of infected wounds of...
Текст визуальный непосредственный
Journal of Pharmaceutical Sciences and Research
Vol.10, Issue8 P. 2027-2029
2018
Статья
Chitosan-miramistin complex (CMC) Chlorhexidine Lysozyme Miramistin Treatment of infected wounds of various genesis
antiinfective agent chitosan chlorhexidine lysozyme miramistin n acetylglucosamine polysaccharide unclassified drug agar diffusion antibacterial activity Article biocompatibility cell proliferation controlled study drug formulation drug potentiation drug stability Escherichia coli fibroblast freeze drying immobilization immune response immunity nonhuman Staphylococcus aureus wound infection
One of modern approaches in the development of new-generation drugs is the design of original dosage forms based on substances of a known spectrum of action using modern innovative technologies that make it possible to obtain drugs with high therapeutic efficiency and with minimal side effects. The invention relates to the pharmaceutical industry and is an innovative pharmaceutical substance, which can be used both independently and in combination with enzymes of the hydrolase class, that are capable of breaking down peptides and proteins, and anesthetic agents for the treatment of infected wounds of various genesis. The chitosan-miramistin complex has multiresistance to antibiotics, enhances functional activity of immune cells by stimulating local nonspecific immunity, promotes antigen capturing by macrophages and its accumulation in the lysosomal fraction, and does not have a local irritant effect. © 2018, Pharmainfo Publications. All rights reserved.